CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 50 enrolled
Drug / intervention
CI-581a +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02539511
NCT02539511Phase 3Completed
CompareCT.gov

The Effect of Brief Potent Glutamatergic Modulation on Disordered Alcohol Use

New York State Psychiatric Institute·interventional·Posted Sep 3, 2015·Updated Feb 11, 2020

In Brief

A Phase 3 clinical trial evaluating CI-581a, CI-581b, and 1 other intervention for Alcohol Dependence. Completed, enrolled 50 participants across 1 site.

Detailed Summary

Alcohol use disorders remain a significant public health problem. The pharmacological facilitation of behavioral treatment represents a promising strategy for addressing disordered drinking. Alcohol use disorders are recognized to be associated with various vulnerabilities that complicate the course of treatment and that may be amenable to glutamate modulators. The purpose of this randomized, double-blind, controlled trial is to test various glutamate modulators in conjunction with motivational enhancement therapy (MET) for alcohol use disorders.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcohol Dependence
CountriesUnited States
CollaboratorsNational Institute on Alcohol Abuse and Alcoholism (NIAAA)

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 3, 2015
Enrollment StartJul 1, 2015
Primary CompletionSep 1, 2017
Study CompletionDec 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 10.8 years ago

Interventions

CI-581adrug

CI-581bdrug

Motivational Enhancement Therapy (MET)behavioral